Targeting the Heat Shock Protein 90 Dimer with Dimeric Inhibitors was written by Kusuma, Bhaskar Reddy;Peterson, Laura B.;Zhao, Huiping;Vielhauer, George;Holzbeierlein, Jeffrey;Blagg, Brian S. J.. And the article was included in Journal of Medicinal Chemistry in 2011.Safety of Methyl 3-bromo-4-fluorobenzoate This article mentions the following:
The design, synthesis, and biol. evaluation of conformationally constrained coumermycin A1 analogs are reported. Compounds were evaluated against both breast cancer (SKBr3 and MCF7) and prostate cancer (PC3 mm2, A549, and HT29) cell lines. Non-noviosylated coumermycin A1 analogs that manifest potent antiproliferative activity resulting from Hsp90 inhibition are provided, wherein replacement of the stereochem. complex noviose sugar with readily available piperidine rings resulted in 闂?100 fold increase in antiproliferative activities as compared to coumermycin A1, producing small mol. Hsp90 inhibitors that exhibit nanomolar activities. In the experiment, the researchers used many compounds, for example, Methyl 3-bromo-4-fluorobenzoate (cas: 82702-31-6Safety of Methyl 3-bromo-4-fluorobenzoate).
Methyl 3-bromo-4-fluorobenzoate (cas: 82702-31-6) belongs to organobromine compounds. Bromo compounds are employed in a variety of metal-catalyzed coupling reactions. They are also ideal candidates for the synthesis of Grignard reagents that have wide-applicability in organic synthesis. alpha-Bromoesters are employed in the Reformatsky reaction for the synthesis of beta-hydroxyesters. Commercially available organobromine pharmaceuticals include the vasodilator nicergoline, the sedative brotizolam, the anticancer agent pipobroman, and the antiseptic merbromin. Safety of Methyl 3-bromo-4-fluorobenzoate
Referemce:
Bromide – Wikipedia,
bromide – Wiktionary